From Frankenstein to gene therapy, a collective responsibility. A glance from (bio)ethics
DOI:
https://doi.org/10.22370/rhv2020iss15pp7-20Keywords:
modificación genética, bioética, ética médica, genoma humano, enfermedad genéticaAbstract
Given the recent developments in biotechnology and genetic engineering, the ability to eliminate genetic diseases from the human genome seems more and more possible each day. Being able to do so would mean a better quality of life for those who would otherwise suffer from incurable genetic diseases.
However, even though the success of such a procedure would bring benefits that cannot be obtained by other means, the consequences for humans are still unknown. As such, the people involved should be held responsible.
The responsibility needs to be collective, not individual, because the decisions leading to the edition of a human genome and someone being born as a result of it are not made by a single individual, but several people, from the prospective parents interested in the intervention for their future child to the ones in charge of performing said intervention.
The addition of the human genome can bring significant benefits, and it seems to be the only way to avoid certain genetic diseases; however, collective responsibility should be taken by those involved in the decisions that lead to a person being born with a modified genome.
References
Berg, P., Baltimore, D., Brenner S., Roblin III, R. O., Singer, M. F. (1975). Summary Statement of the Asilomar Conference on Recombinant DNA Molecules. Proceedings of the National Academy of Sciences of the United States of America, 72(6): 1981–1984. doi: https://doi.org/10.1073/pnas.72.6.1981
Blaese, R. M. et al (1995). Lymphocyte-Directed Gene Therapy for ADA− SCID- Initial Trial Results After 4 Years. Science, 270(5235): 475–480. doi: https://doi.org/10.1126/science.270.5235.475
Bratman, M. E. (1992). Shared Cooperative Activity. The Philosophical Review, 101(2): 327-341. doi: https://doi.org/10.2307/2185537.
Jonas, Hans (2015). El principio de responsabilidad. Ensayo de una ética para la civilización tecnológica. España: Herder.
Kosicki, M., Tomberg, K., Bradley, A. (2018). Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nature biotechnology, 36(8): 765–771. doi: https://doi.org/10.1038/nbt.4192
Ledford, Heidi. (2019): Super-precise new CRISPR tool could tackle a plethora of genetic diseases. Nature, 574: 464-465. doi: https://doi.org/10.1038/d41586-019-03164-5
LeMieux, J. (2018): Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements. Genetic Engineering and Biotechnology News. https://www.genengnews.com/insights/another-crispr-calamity-u-k-team-reports-crispr-induced-gene-rearrangements/. Consulta: 11/08/2020
Liang, P. et al (2015): CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & cell, 6: 363–372. doi: https://doi.org/10.1007/s13238-015-0153-5
Luria, S. E. (1968). The Microbiologist and His Times. Bacteriological Reviews, 32(4): 401–403.
Ma, H. et al (2017). Correction of a pathogenic gene mutation in human embryos. Nature, 548: 413-419. doi: https://doi.org/10.1038/nature23305
Miller, S. (2001). Collective Responsibility. Public Affairs Quarterly, 15(1): 65–82.
Regalado, A. (2018). Turns out CRISPR editing can also vandalize genomes. MIT Technology Review. https://www.technologyreview.com/f/611659/turns-out-crispr-editing-can-also-vandalize-genomes/. Consulta: 11/08/2020
Rogers, S., Lowenthal, A., Terheggen, H. G., Columbo, J. P. (1973). Induction of Arginasa Activity with the Shope Papilloma Virus in Tissue Culture Cells From an Argininemic Patient. Journal of Experimental Medicine, 137(4): 1091–1096. doi: https://doi.org/10.1084/jem.137.4.1091
Shelley, Mary (2000). Frankenstein o el moderno Prometeo. España: Ediciones Siruela.
Nobel Media AB. (2020). Renato Dulbecco-Facts. The Nobel Prize. https://www.nobelprize.org/prizes/medicine/1975/dulbecco/facts/. Consulta: 11/08/2020
Wirth, T., Parker, N., Ylä-Herttuala, S. (2013). History of gene therapy. Gene, 525(2): 162–169. doi: https://doi.org/10.1016/j.gene.2013.03.137
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication, with the work after publication simultaneously licensed under a Creative Commons Attribution License (CC BY-NC-ND 4.0 International) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
